Fresh analysis indicates that people who discontinue new GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who end traditional diet and exercise programs.
Research printed in a prominent health publication shows that while obese people frequently drop about a fifth of their total mass while undergoing treatment, the mass comes back at an average rate of nearly a kilo each month once they quit.
"People purchasing such treatments should be cognizant of the danger of fast weight regain when the treatment ends," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery implies a return to starting mass within about one and a half years.
Comparing Treatments
The research, which reviewed dozens of trials involving thousands of patients, compared the results of the injectable medications with older methods.
The team note that individuals who shed pounds through lifestyle changes alone usually have a more gradual creep back—perhaps 0.1 kg a month—post-intervention.
Explaining the Quick Rebound
Experts believe the mode of action of the drugs accounts for the amplified regain.
These medications imitate a body's own chemical called GLP-1, which controls feelings of fullness.
"Artificially providing the hormone levels far above than the body's typical production might result in the system to produce less of its endogenous hormone, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication results in appetite is uncontrolled, making overeating a significant risk."
A Lifelong Condition?
The NHS advise the injections for individuals with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Professionals argue that, given the high risk of relapse, the treatment is often ongoing.
This view is echoed by pharmaceutical companies, who state that the results "emphasize the chronic character of obesity," similar to managing conditions like hypertension.
Patient Accounts
Individuals who have come off the jabs describe a intense return of hunger.
"I experienced a switch flipping and you become ravenous," said a patient.
The struggle is exacerbated if users have not established permanent dietary or behavioural modifications during therapy.
Significant Interest
Survey data indicate that millions of adults in the UK have tried these injections in the last 12 months, with desire remaining high.
- Use is greater among females compared to men.
- The middle-aged demographic shows the highest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
Finally, researchers emphasize that while these medications are effective tools for weight loss, they are not a magic fix and long-term success likely depends on integrated behavioural changes.
